Literature DB >> 15963476

(1)H magnetic resonance spectroscopy of autosomal ataxias.

Martin Viau1, Luc Marchand, Céline Bard, Yvan Boulanger.   

Abstract

Multiple forms of autosomal ataxia exist which can be identified by genetic testing. Due to their wide variety, the identification of the appropriate genetic test is difficult but could be aided by magnetic resonance data. In this study, magnetic resonance spectroscopy (MRS) and imaging (MRI) data were recorded for 20 ataxia patients of six different types and compared to 20 normal subjects. Spectra were acquired in the pons, left frontal lobe, left basal ganglia, left cerebellar hemisphere and vermis. Both metabolite spectra and absolute metabolite concentrations were determined. Differences in metabolite levels were observed between ataxia patients and control subjects and between ataxia patients of different types. A number of correlations were found between metabolite ratios, atrophy levels, number of repeats on the small and large allele, age at examination, symptoms duration and age at symptoms onset for ataxia patients. These MR characteristics are expected to be useful for the identification of the ataxia type.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15963476     DOI: 10.1016/j.brainres.2005.05.015

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Regional neurochemical profiles in the human brain measured by ¹H MRS at 7 T using local B₁ shimming.

Authors:  Uzay E Emir; Edward J Auerbach; Pierre-Francois Van De Moortele; Małgorzata Marjańska; Kamil Uğurbil; Melissa Terpstra; Ivan Tkáč; Gülin Oz
Journal:  NMR Biomed       Date:  2011-07-15       Impact factor: 4.044

2.  Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy.

Authors:  Gülin Oz; Isabelle Iltis; Diane Hutter; William Thomas; Khalaf O Bushara; Christopher M Gomez
Journal:  Cerebellum       Date:  2011-06       Impact factor: 3.847

3.  Combined Cerebellar Proton MR Spectroscopy and DWI Study of Patients with Friedreich's Ataxia.

Authors:  Laura Ludovica Gramegna; Caterina Tonon; David Neil Manners; Antonella Pini; Rita Rinaldi; Stefano Zanigni; Claudio Bianchini; Stefania Evangelisti; Filippo Fortuna; Valerio Carelli; Claudia Testa; Raffaele Lodi
Journal:  Cerebellum       Date:  2017-02       Impact factor: 3.847

4.  Morphometry and 1H-MR spectroscopy of the brain stem and cerebellum in three patients with fragile X-associated tremor/ataxia syndrome.

Authors:  A Ginestroni; L Guerrini; R Della Nave; C Tessa; E Cellini; M T Dotti; P Brunori; N De Stefano; S Piacentini; M Mascalchi
Journal:  AJNR Am J Neuroradiol       Date:  2007-03       Impact factor: 3.825

5.  (1)H MR spectroscopy in Friedreich's ataxia and ataxia with oculomotor apraxia type 2.

Authors:  Isabelle Iltis; Diane Hutter; Khalaf O Bushara; H Brent Clark; Myron Gross; Lynn E Eberly; Christopher M Gomez; Gülin Oz
Journal:  Brain Res       Date:  2010-08-14       Impact factor: 3.252

6.  Metabolic evidence for cerebral neurodegeneration in spinocerebellar ataxia type 1.

Authors:  Sarah Doss; Alexander U Brandt; Timm Oberwahrenbrock; Matthias Endres; Friedemann Paul; Jan Leo Rinnenthal
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

Review 7.  Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.

Authors:  Meng-Ling Chen; Chih-Chun Lin; Liana S Rosenthal; Puneet Opal; Sheng-Han Kuo
Journal:  J Neurol Sci       Date:  2021-04-01       Impact factor: 3.181

Review 8.  Spinocerebellar ataxia clinical trials: opportunities and challenges.

Authors:  Sarah M Brooker; Chandrakanth Reddy Edamakanti; Sara M Akasha; Sheng-Han Kuo; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2021-05-21       Impact factor: 4.511

Review 9.  Neuroimaging Biomarkers in SCA2 Gene Carriers.

Authors:  Mario Mascalchi; Alessandra Vella
Journal:  Int J Mol Sci       Date:  2020-02-04       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.